short and long-term safety of the 2009 as03-adjuvanted pandemic vaccine短期和长期2009 as03-adjuvanted大流行性流感疫苗的安全性.pdfVIP

Short and Long-Term Safety of the 2009 AS03- Adjuvanted Pandemic Vaccine 1,2 ´ 1 3 1 4 Gaston De Serres *, Marie-Claude Gariepy , Brenda Coleman , Isabelle Rouleau , Shelly McNeil , ´ ˆ 1, Allison McGeer3, Ardith Ambrose4, Judy Needham5, Chantal Bergeron6, Melanie Benoıt Cynthia Grenier7, Kenna Sleigh8, Arlene Kallos5, Manale Ouakki2, Najwa Ouhoummane2, Grant Stiver8, Louis Valiquette7, Anne McCarthy6, Julie Bettinger5 on behalf of the PHAC-CIHR influenza Research Network (PCIRN) ´ ´ 1 Centre de recherche du CHUQ-CHUL, Laval University, Quebec City, Quebec, Canada, 2 Institut national de sante publique du Quebec (INSPQ), Quebec City, Quebec, Canada, 3 Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada, 4 Canadian Center for Vaccinology, Halifax, Nova Scotia, Canada, 5 Vaccine Evaluation Center, BC Children’s Hospital and the University of British Columbia, Vancouver, British Columbia, Canada, 6 The Ottawa General Hospital, Ottawa, Ontario, Canada, ´ 7 Universite de Sherbrooke, Sherbrooke, Quebec, Canada, 8 University of British Columbia, Vancouver, British Columbia, Canada Abstract Background: This study assessed the short and the long term safety of the 2009 AS03 adjuvanted monovalent pandemic vaccine through an active web-based electronic surveillance. We compared its safety profile to that of the seasonal trivalent inactivated influenza vaccine (TIV) for 2010–2011.